Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Raloxifene Reduces Risk of Invasive Estrogen Receptor-Positive Breast Cancer BETHESDA, Md -- June 10, 2008 -- Women who took raloxifene were less likely to develop invasive estrogen receptor (ER)-positive breast cancer compared with women who did not, according to data from a randomised controlled trial published online today in the Journal of the National Cancer Institute. However, the drug did not reduce the risk of noninvasive cancer or invasive ER-negative cancers. A previous analysis of data from the Raloxifene Use for the Heart (RUTH) trial, which enrolled women with coronary heart disease or those at an increased risk for the disease, showed that the drug did not protect against heart disease, which was one of the primary aims of the trial. But after a median follow up of 5.6 years, it did reduce the risk of invasive breast cancer by 44% compared with women not taking the drug. To investigate the specific types and stages of breast cancer affected by raloxifene, as well as the timing of its action and the types of patients it can help, Deborah Grady, MD, University of California at San Francisco, San Francisco, California, and colleagues examined the RUTH trial data in more detail. The 5,044 women who took raloxifene had a 55% reduction in the risk of developing invasive ER-positive breast cancer compared with the 5,057 women who took placebo. That is equivalent to an absolute reduction in risk of 1.2 cases per 1,000 women treated for 1 year. There was no reduction in the risk of invasive ER-negative breast cancer or in noninvasive breast cancers of any type. The researchers saw the same effects regardless of the women's age, prior hormone use, or baseline risk of breast cancer. The reduction in breast cancer risk is consistent with findings from other trials that involved women without heart disease. Women who took raloxifene in the RUTH trial had an increased incidence of blood clots and fatal strokes compared with those who took placebo. Thus, the researchers conclude that women who are considering taking raloxifene need to weigh the risks and benefits. "Assuming that the relative risks from the RUTH trial apply to women in the general population, the best benefit-to-risk ratio would occur in women at high risk of breast cancer and osteoporosis and low risk of venous thrombosis and stroke," the authors wrote. SOURCE: Journal of the National Cancer Institute E-mail this page to a friend or colleague! To print, use this version